B2RLaw has advised Auxilius Pharma and its founders on receiving investments from venture capital investors CofounderZone Corporate Angel Fund ASI and Augebit together with several business angels and existing investors. SSW Pragmatic Solutions advised CofounderZone.
Kinstellar and Wise3 Advise on Powerful Medical EUR 6.2 Million Seed Round
Kinstellar has advised Powerful Medical on its EUR 6.2 million seed funding round from investors including Arieli Capital, Venture To Future Fund, CB ESPRI Impact One, BPD partners, and several angel investors. Wise3 advised CB ESPRI Impact One.
Coman Mindru Popescu Successful Against Romanian Authorities in Avastin Dispute
Coman Mindru Popescu has successfully represented Chenda Filoteia against Romania's Ministry of Health, National Health Insurance House, and National Agency for Medicines and Medical Devices in a dispute over national health insurance coverage of the usage of Avastin for the glioblastoma therapeutic indication.
Corporate Criminal Liability in Poland – Changes to Affect Life Sciences & Healthcare
The Life Sciences & Healthcare industry is not free of criminal activity that may give rise to the companies’ liability for criminal offences. However, the corporate criminal liability in Poland is not effectively enforced now. The government presented its proposal to change that in the new draft law amending the Corporate Criminal Liability Act (the “draft”).
DGKV Advises Invenio Partners Fund II on SAT Health Investment
Djingov Gouginski Kyutchukov & Velichkov has advised the Invenio Partners Fund II SCSP on its EUR 3 million investment in SAT Health.
SSK&W Advises CofounderZone and Business Angels on Investment in Carein
SSK&W Stoklosa Syp & Wspolnicy has advised CofounderZone and business angels including Mateusz Bodio and Bartosz Hojka on investing in Carein.
Schoenherr Advises on Eucodis Bioscience Sale to Biosynth Group
Schoenherr has advised the shareholders of Vienna-headquartered biotech company Eucodis Bioscience on the sale of the company to the Biosynth Group. Reportedly, Gibson Dunn & Crutcher and E+H advised the Biosynth Group.